Thus, an early application of the ACE2-Mb TM in combination with the EM of the UniMAB system would be favorable, especially for patients with a high risk of severe COVID-19, as it would not only exert its virus-neutralizing and anti-inflammatory functions but also redirect the patient ́s T-cells to kill virus-infected cells by forming a complex with the EM. The gene discussed is ACE2; the disease is COVID-19.